Introduction
The correct functioning of the ubiquitin-proteasome pathway is essential for the degradation of the majority of intracellular proteins. Several key regulatory proteins involved in cell proliferation and differentiation are regulated by proteasome-mediated proteolysis resulting in the activation or inhibition of specific cell signaling pathways (Adams, 2004a) . The proteasome is also central to the regulation of cell death and apoptosis. The proapoptotic Bcl-2 family proteins Bim, Bik and Bid, which regulate the release of proapoptotic factors such as cytochrome c and Smac from mitochondria, are known substrates for targeted ubiquitination and degradation (Breitschopf et al., 2000; Marshansky et al., 2001; Ley et al., 2003) . Indeed, caspases, the key proteases activated during apoptosis, are also regulated by the proteasome. An endogenous caspase inhibitor family of proteins, the inhibitor of apoptosis (IAPs), not only inhibit active caspases but also target them for destruction by acting as ubiquitin ligases and promoting polyubiquitination of activate caspases (Huang et al., 2000; Suzuki et al., 2001) .
In recent years modulation of proteasomal function with specific inhibitors has evolved as a novel target for the treatment of cancers such as multiple myeloma (Chauhan et al., 2005) as well as lung, colon and prostate cancer (Aghajanian et al., 2002; Papandreou et al., 2004; Chauhan et al., 2005) . Proteasome inhibitors (PIs) have been demonstrated to overcome chemoresistance of tumor cells by enhancing chemosensitivity and even acting in synergy with other agents to induce apoptotic cell death of tumor cells (Adams, 2002; Park and Lenz, 2004) . Indeed, clinical efficiency of Bortezomib (PS-341/Velcade), a reversible PI has recently been observed in multiple myeloma patients (Richardson et al., 2003) . Inhibitors with a broader specificity and irreversible binding have likewise been identified and are currently being tested in preclinical trials (Melino, 2005) . One such inhibitor is epoxomicin (Epoxo), a naturally found a 0 , b 0 epoxyketone peptide, which is a highly selective and irreversible inhibitor of the chymotryptic-, tryptic-and post-glutamyl peptidyl hydrolytic-like activities of the proteasome (Meng et al., 1999) , and was first identified and isolated from a species of actinomycetes on the basis of its antitumor activity (Hanada et al., 1992) . Unlike several widely used PIs, Epoxo is highly specific for the proteasome without affecting the activity of other non-proteasomal proteases including calpain, trypsin and cathepsin B (Meng et al., 1999) .
In addition to the post-translational modification of proapoptotic proteins, inhibition of proteasomal function may also regulate several transcription-dependent processes. Indeed, the activity of several transcription factors, including p53 and nuclear factor kappa B (NF-kB) (Chowdary et al., 1994; Palombella et al., 1994) , are known to be modulated by proteasome activity. This study was undertaken to analyse the underlying transcriptional mechanisms leading to apoptosis triggered by inhibition of the proteasome system in cancer cells. Our data demonstrates that although the two Bcl-2-homology domain 3-only (BH3-only) genes p53 upregulated modulator of apoptosis (PUMA) and Bim are transcriptionally activated by proteasome inhibition, p53-dependent activation of PUMA plays a predominant role in this type of cell death.
Results
Inhibition of proteasome function using Epoxo induces caspase activity and apoptosis To investigate the ability of Epoxo to inhibit proteasomal activity and induce apoptosis in human SH-SY5Y neuroblastoma cells we treated cells with 50 nM Epoxo for varying time periods. Western blot analysis of monoand poly-ubiquitinylated proteins demonstrated a timedependent increase in the levels of ubiquitinylated proteins, characteristic of proteasome dysfunction and stress, especially following 16 and 24 h treatment with 50 nM Epoxo (Figure 1a) . The increased levels of ubiquitinylated proteins was followed by an activation of DEVDase activity, indicative of the activation of the effector caspases -3 and -7 during this process (Figure 1b) . Epoxo also led to the release of cytochrome c from mitochondria ( Figure 1c ) and increased levels of apoptosis as detected by annexin V binding (Figure 1d ). Further analysis using Hoechst staining revealed condensation and fragmentation of most nuclei. Coincubation with the pan-caspase inhibitor, zVAD.fmk, inhibited these nuclear morphological changes indicating that caspases are critically involved in proteasome inhibition-induced apoptosis (Figure 1e ). 
Microarray analysis of transcriptional response to proteasome inhibition by Epoxo
In an effort to identify apoptotic pathways involved in Epoxo-induced cell death we utilized high-density microarrays to investigate the transcriptional changes occurring after Epoxo treatment. A 16 h treatment was chosen as a suitable time point to analyse differences in gene expression owing to the fact that at this time point, inhibition of the proteasome was clearly evident (Figure 1a ) but preceded the major increase in caspase activity and apoptosis (Figure 1b, d ). The microarray experiment was performed in duplicate with the threshold for differentially expressed up-and downregulated genes set at >2.8-fold/o2.8-fold (median value of both samples) and >3.0-fold/o3.0-fold in at least one of the duplicate samples. Using this approach we identified 296 genes upregulated and 209 downregulated genes following Epoxo treatment. Table 1 Genes involved in protein folding in the cytosol. Consistent with disturbances in protein turnover and the accumulation of protein aggregates within the cytosol was the transcriptional activation of several genes involved in aiding protein folding. In fact, heat-shock protein (Hsp)70B, a potent molecular chaperone, was identified as the highest induced gene (>700-fold from microarray data). Other members of this group induced include Hsp40, Hsp-B1, as well as several DNAJB chaperones. Significantly, all the chaperones identified are involved in protein folding within the cytosol and are not associated with protein folding within the endoplasmic reticulum (ER). This differs from the transcriptional response to ER stress, which we have previously profiled in the identical cellular system (Reimertz et al., 2003) . Here, proteasome inhibition does appear to induce immunoglobulin heavy chainbinding protein/78 kDa glucose-regulated protein expression although the impairment of ER-associated protein degradation (ERAD) may result in the accumulation of misfolded proteins within the ER and the subsequent induction of ER stress response.
Genes involved in proteasomal function. The microarray data identified differential expression of several genes involved in the function of the proteasome. These included genes encoding the 26S proteasome subunits 11, 13, S1 and p55. Indeed, previous studies have demonstrated transcriptional induction of proteasomal subunits following proteasomal inhibition (Meiners et al., 2003) .
Transcriptional regulators. Proteasomal stress resulted in increased expression of several members of the C/ enhancer binding protein (EBP) family of transcription factors including C/EBP-homologous protein (CHOP), C/EBP beta and C/EBP gamma. Similarly, two members of the ATF transcription factor family, ATF-2 and ATF-3, were also induced. In addition, the microarray analysis also revealed a transcriptional activation of both c-Jun and c-fos. The most prominently downregulated genes after proteasome inhibition were members of the c-Myc family of transcription factors which control expression of genes involved in cell growth and metabolism (Dang, 1999) .
Cell cycle regulation. Several genes involved in the control of the cell cycle were found to be differentially expressed. These included cyclin T2 and the p53 target genes Waf1 and Mdm2, suggesting that Epoxo treatment is associated with induction of p53-dependent cell signaling and induction of cell cycle arrest. Given that p53 expression levels and signaling is regulated by ubiquitination by Mdm2, the identification of p53-dependent targets is consistent with inhibition of proteasomal function.
Antioxidant defence. Consistent with previously published data that suggest proteasomal stress is associated with increases in the production of reactive oxygen species (Kikuchi et al., 2003) , is the transcriptional activation of several genes involved in the defence against oxidative stress. These include genes involved in the regeneration of the antioxidant protein glutathione (glutathione reductase) as well as the antioxidant genes, heme oxygenase-1 (HO-1) and glutathione peroxidase.
Proteasomal inhibition induces expression of the BH3-only proteins Bim and PUMA A large functional group of upregulated genes were those involved in the regulation of apoptosis. Amongst those identified in this group included the death receptors Fas/ Apo1 and TRAIL-R2 as well as several members of the Bcl-2 family of proteins including the BH3-only members, Bim and PUMA. Transcriptional activation of BH3-only proteins plays a central role in the induction of apoptosis by a plethora of stimuli by creating an imbalance between proapoptotic and antiapoptotic Bcl-2 proteins resulting in the release of cytochrome c and apoptosis (Villunger et al., 2003a; Willis and Adams, 2005) . Because of the evidence of cytochrome c release in our model and in previous studies employing PIs (Wagenknecht et (Figure 3b , right panel), as BimEL has previously been shown to be targeted for degradation by the ubiquitin-proteasome pathway (Ley et al., 2003) . Based on these observations, we conclude that enhanced Bim expression is triggered by two distinct mechanisms after proteasome inhibition: post-translational protein stabilization and a delayed induction of Bim transcription. In order to delineate whether PUMA or Bim expression were required during proteasome inhibition-induced apoptosis we isolated primary mouse embryonic fibroblasts (MEFs) from PUMA and Bim knockout mice and treated them with Epoxo. Loss of PUMA or Bim expression did not affect levels of proteasomal stress with similar levels of ubiquitinylated proteins evident in wild type (WT), PUMAÀ/À and BimÀ/À cells following Epoxo treatment (Figure 3a) . However, caspase activity was significantly attenuated in PUMAÀ/À MEFs, although loss of Bim expression had no significant effect (Figure 3b ). To quantify the number of cells undergoing apoptosis, we performed Hoechst staining 24 h post-Epoxo treatment. As observed with the caspase activity assay, levels of apoptosis were markedly reduced in PUMAÀ/À MEFS whereas loss of Bim expression afforded no significant protection (Figure 3c ). Taken together these results suggest that PUMA may be a major contributor to proteasome inhibition-induced apoptosis.
Induction of PUMA is p53-dependent PUMA has been identified as a key mediator of the p53-dependent apoptotic response (Nakano and Vousden, 2001; Yu et al., 2001) . However, induction of PUMA following growth factor withdrawal (Han et al., 2001) and ER stress (Reimertz et al., 2003) has been demonstrated to occur in a p53-independent manner. In order to investigate whether p53 was required for PUMA induction following proteasomal stress we utilized luciferase reporter assays employing a WT and a mutant PUMA promoter, where the p53 binding site is disrupted by point mutations (Han et al., 2001) . Treatment of HeLa cells with 50 nM Epoxo for 24 h induced significant elevation of luciferase activity indicative of activation of the PUMA promoter (Figure 4a) . Use of the construct with the mutated p53 binding site dramatically reduced the ability of Epoxo to activate the PUMA promoter, suggesting that PUMA expression during proteasomal stress is largely p53-dependent (Figure 4a) . In order to further characterize this response we treated WT and p53À/À HCT116 cells with 50 nM Epoxo. Western blotting demonstrated that the levels of mono-and poly-ubiquitinylated proteins following Epoxo treatment were comparable in both WT and p53À/À HCT cells demonstrating that both cell types experienced similar amounts of proteasomal stress, independent of their p53 status (Figure 4b) . On a mRNA level WT HCT cells showed an early induction of PUMA mRNA following Epoxo treatment. However, this induction of PUMA was effectively ablated in p53À/À HCT cells demonstrating that PUMA induction during proteasomal stress is p53-dependent. In contrast, the expression of Chop mRNA was induced to similar levels in both cell types irrespective of p53 status (Figure 4c ).
Both p53 and PUMA are required for proteasomal stress-induced apoptosis To further characterize the requirement for PUMA during Epoxo-induced cell death in human cancer cells we treated WT and PUMAÀ/À HCT cells with 50 nM Epoxo for various time periods and analysed whole-cell lysates for DEVDase activity. Both WT and PUMAÀ/À cells experienced similar levels of proteasomal stress as assessed by Western blotting of ubiquitinylated proteins (Figure 5a ). Time course analysis of DEVDase activity following treatment with Epoxo revealed that the WT HCT cells induced a time-dependent activation of caspases with significant levels of caspase activity detectable following 12 h treatment. Interestingly, the PUMAÀ/À cells displayed delayed kinetics of caspase activation following Epoxo treatment with significant levels of caspase activation only detectable following 16 h treatment. Indeed, the caspase activity in PUMAÀ/À cells was significantly attenuated compared to the levels in WT cells especially at the 16-24 h time point (Figure 5b) . In order to further delineate the role of p53 and PUMA during proteasomal stress-induced apoptosis we examined caspase activity and apoptosis in WT, p53À/À and PUMAÀ/À HCT cells treated with 50 nM Epoxo. Both caspase activity and apoptosis were significantly attenuated in both p53À/À and PUMAÀ/À HCT cells compared to HCT WT controls (Figure 5c and d). To further investigate the potential role of Bim in the residual Epoxo-induced apoptosis observed in p53À/À and PUMAÀ/À HCT cells, we transiently knocked down Bim expression in WT, p53À/À and PUMAÀ/À HCT cells by RNA interference. As (Figure 5f ). Interestingly, knockdown of Bim expression also did not confer any detectable protection from Epoxoinduced cell death in the absence of PUMA or p53 expression (Figure 5f ). Taken together these results demonstrate that the p53/PUMA pathway, but not Bim is required for Epoxo-induced caspase activation and cell death.
Discussion
Despite abundant evidence for the therapeutic potential of PIs in a variety of malignancies, the relevant signaling pathways leading to apoptosis triggered by proteasome inhibition in cancer cells are not clearly defined. In this study, we demonstrate that treatment of neuroblastoma cells with the highly potent and selective PI Epoxo impairs protein degradation and subsequently induces activation of caspases and apoptosis. In our model prolonged proteasome inhibition was associated with the concomitant induction of two members of the proapoptotic BH3-only family, PUMA and Bim. Interestingly, PUMA induction occurred in a p53-dependent manner and cells deficient in PUMA expression were significantly protected from Epoxo-induced caspase activation, suggesting a requirement for PUMA during proteasomal stress-induced apoptosis. Transcriptional activation and increased expression of BH3-only proteins is central in determining cell fate in response to a variety of stimuli, functioning as activation enablers and transducing the cellular stress signal to other proapoptotic Bcl-2 family members such as Bax and Bak (for review see Willis and Adams (2005) ).
Owing to the broad number of substrates of the proteasome, a significant number of players have been previously implicated in the proapoptotic activity of PIs, among them NF-kB, p53, Bcl-2 and caspases (for review see Adams (2004b) ). NF-kB is constitutively activated in many cancer cells and is associated with cancer development and progression (Karin, 2006) . NF-kB potently inhibits apoptosis by activation of antiapoptotic target genes such as Bcl-xL and IAPs) (Luo et al., 2005) . As IkBa the endogenous inhibitor of NF-kB is continuously degraded via the proteasome pathway, PIs act as indirect inhibitors of NF-kB (Karin and BenNeriah, 2000) . Indeed, inactivation of NF-kB has been suggested to play a major role in the antitumor effect of the PI, Bortezomib (Velcade/PS-341), in multiple myeloma (Hideshima et al., 2002) and melanoma cells (Amiri et al., 2004) . Despite these observations, inhibition of NF-kB is not required to sensitize hepatocellular carcinoma cells, keratinocytes and lymphoma cells to apoptosis (Kurland and Meyn, 2001; Leverkus et al., 2003; Ganten et al., 2005) . Our microarray analyses in SH-SY5Y neuroblastoma cells did not detect noticeable expression changes in NF-kB-dependent cell death regulators, such as Bcl-2, Bcl-xL, and the IAPs (data not shown), and subsequent real-time qPCR analysis in HCT colon cancer cells also failed to detect any significant changes in the expression of these genes (Supplementary Figure 2) . These data suggest that inhibition of NF-kB might not play a major role in apoptosis induced by PIs in a significant number of cancer types.
Similar controversy exists on the correlation between the apoptosis-inducing efficiency of PIs and the p53 status of various types of cancer cells, mainly owing to the fact that this correlation seems to be cell typedependent. Although PIs have been shown to induce p53-independent apoptosis in glioma cells (Wagenknecht et al., 1999; Yin et al., 2005) , the majority of reports suggest that PIs induce a p53-dependent form of apoptosis in most cancer cell types, such as leukemia cells (Shinohara et al., 1996; Masdehors et al., 2000) , as well as melanoma and myeloma cells (Qin et al., 2005) . Consistent with previous studies we observed a prominent increase of p53 levels, which was associated with transcriptional activation of the proapoptotic BH3-only gene PUMA. Interestingly, ATF3, a recently identified positive regulator of p53 stability (Yan et al., 2005) , was also found to be transcriptionally induced and may represent a positive feed back loop further amplifying p53 activation during proteasomal stress. Of note, it has been previously reported that PUMA accounts for most of the p53-dependent apoptosis in the HCT116 colon carcinoma cells employed in this study (Yu et al., 2001 (Yu et al., , 2003 . In our experiments, the extent of protection against Epoxo-induced cell death was very similar in p53-deficient and PUMA-deficient HCT116 cells, suggesting that p53 mediates cell death largely through PUMA induction, and that other transcriptional, proapoptotic targets of p53 such as Fas (Owen-Schaub et al., 1995) and Trail-R2 (Wu et al., 1997) may play a less pronounced role, although they may additionally sensitize cells to therapies involving death ligands. Interestingly, the most potently downregulated gene following proteasome inhibition was the oncogenic transcription factor, c-myc, which may have a role in the antitumorigenic effect of PIs. Furthermore, c-myc has been shown to have an inhibitory effect on p53-dependent target gene expression and apoptosis (Ceballos et al., 2005) .
Consistent with previous reports we found increased expression of Bim following inhibition of the proteasome (Nikrad et al., 2005) , however, our data argues against a significant role of Bim in our model. Interestingly, in agreement with our findings a recent study demonstrated increased Bim expression following proteasome inhibition, although siRNA-mediated knockdown of Bim afforded no protection (Anan et al., 2006) . However, it remains plausible that increased expression of Bim in response to PIs may be of therapeutic benefit when used in combination with other agents such as TRAIL and paclitaxel (Nikrad et al., 2005; Tan et al., 2005) . In our model a lack of PUMA expression was sufficient to offer significant protection, suggesting that Bim induction is not able to compensate for PUMA deficiency as has been reported for other BH3-only proteins in some models (Villunger et al., 2003a, b) . However, although loss of Bim expression afforded no protection in the cell lines employed in this study it is still possible that PUMA and Bim have overlapping action during proteasomal-stress-induced apoptosis in certain cell types which may be best addressed by studying cells from BimÀ/ÀPUMAÀ/À double knockout mice. Interestingly, several recent studies have also demonstrated a concomitant induction of Bim and PUMA following treatment with the oxidative stress-inducing agents 6-OHDA (Biswas et al., 2005) and arsenite (Wong et al., 2005) . In both scenarios the inhibition of PUMA expression was found to be sufficient to dramatically reduce the extent of apoptosis, whereas loss of Bim expression incurred no advantage with equivalent levels of cell death seen in WT and BimÀ/À cells (Biswas et al., 2005; Wong et al., 2005) . Hence, scenarios exist where both PUMA and Bim are induced, but PUMA plays a more prominent role for the execution of cell death.
Curiously, these functional studies argue against a recent study suggesting that a Bim BH3 peptide may be a more potent inducer of cytochrome c release and apoptosis than its PUMA counterpart (Kuwana et al., 2005) , suggesting that potency of BH3-only proteins may also be dependent on functional interactions with other molecules within the dynamic environment of a cell.
We have previously shown that cell death triggered by ER stress also requires the transcriptional upregulation of PUMA (Reimertz et al., 2003) . Defects in proteasome-mediated protein degradation trigger similar cellular stress responses as observed during ER stress, such as attenuation of protein synthesis and induction of transcription factors of the ATF and C/EBP families (Reimertz et al., 2003) suggesting PUMA expression is a general response to mediate cell death during prolonged defects in protein quality control and protein degradation. Our data emphasizes the fundamental importance of the p53/PUMA pathway in determining the level of sensitivity of cancer cells to PIs.
Materials and methods

Materials
Caspase substrate acetyl-DEVD-7-amido-4-methylcoumarin (Ac-DEVD-AMC) and inhibitor z-Val-Ala-Asp (O-methyl)-fluoromethyl ketone (zVAD.fmk) was from Bachem (St Helen's, UK). Epoxo and Hoechst 33258 were purchased from Sigma-Aldrich (Tallaght, Dublin, Ireland). All other chemicals came in analytical grade purity from Sigma-Aldrich (Tallaght, Dublin, Ireland).
Cell lines and culture
Human SH-SY5Y neuroblastoma cells, HeLa, HCT116 WT, HCT116 p53À/À and HCT116 PUMAÀ/À cells were grown in Rosewell Park Memorial Institute medium 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin, in a humidified atmosphere of 5% CO 2 in air at 371C. Primary MEFs were isolated from WT, PUMAÀ/À or BimÀ/À in a C57/BL/6 background from E14.5 day embryos using standard methods and were maintained in Dulbecco's modified Eagle's medium with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, and 100 mg/ml streptomycin, in a humidified atmosphere of 5% CO 2 in air at 37 o C. For all experiments fibroblasts were used between passages 1-3. The generation of the PUMAÀ/À and BimÀ/À mice have been described previously (Bouillet et al., 1999; Villunger et al., 2003a) .
Microarray analysis SH-SY5Y neuroblastoma cells were treated with 50 nM Epoxo or vehicle (0.1% dimethylsulfoxide (DMSO)) for 16 h. Total RNA of duplicate samples was extracted using the RNeasy Midi Kit (Qiagen, Hilden, Germany). Complementary RNA was synthesized from 40 mg of the total RNA by using the Superscript Choice Kit (Invitrogen, Paisley, UK). The cRNA was prepared and biotin-labeled by in vitro transcription (Enzo Biochemical, Farmingdale, NY, USA). Labeled cRNA was fragmented and hybridized for 16 h at 451C to an HG-U95Av2 array (Affymetrix, Santa Clara, CA, USA). Hybridization, washing and staining, as well as scanning of the gene chips in a GeneArray Scanner (Agilent Technologies, Palo Alto, CA, USA) were performed as described in the Affymetrix Gene Expression Analysis Technical Manual. The Affymetrix Microarray Suite 5.0 was used to analyse the relative abundance of each gene from the average difference of intensities. For each individual gene, the signal ratio between perfect match and mismatch probe cells was used to determine its 'Absolute Call', indicating whether the corresponding transcript was present (P), absent (A), or marginal (M). For analysis of differential target gene expression, the 'Difference Call Decision Matrix' was employed. Individual transcript levels were ranked as either increased (I), marginally increased (MI), decreased (D), marginally decreased (MD) or not changed (NC). To be considered as upregulated, the Absolute Call of individual transcripts had to be present, and the Difference Call had to be increased in both duplicate samples. To be considered as downregulated, the Absolute Call of individual transcripts had to be present in the control samples (DMSO), and the Difference Call had to be decreased in both duplicate samples.
Real-time qPCR
Total RNA was extracted using the RNeasy mini Kit (Qiagen). First strand cDNA synthesis was performed using 2 mg of total RNA as template and Moloney murine leukemia virus reverse transcriptase (Invitrogen) primed with 50 pmol of random hexamers. Quantitative real-time PCR was performed using the LightCycler (Roche Diagnostics, Basel, Switzerland) and the QuantiTech SYBR Green PCR kit (Qiagen) as per manufacturer's protocol. Specific primers for each gene analysed were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Sense and antisense primers were: ATCTCAGTGCAATGGCTTCC and CAATGCATTCTCCACACCAG for Bim; GACGACCTC AACGCACAGTA and CACCTAATTGGGCTCCATCT for PUMA; GCCGAGAGAAAACAGTCCAG and GCCGAGA GAAAACAGTCCAG for WAF1; CCCCAAGATCCTGAAA CAGA and CCGTTGCTGGACTGGATTAT for cJun; GGCAAGGAGCTGAACAAGAG and GATAGTGGCGTTC CTCTGGA for Hsp70b; GGTCCTGTCTTCAGATGAAAA TG and CTTGGTGCAGATTCACCATTC for Chop. Each primer pair was tested with a logarithmic dilution of a cDNA mix to generate a linear standard curve, which was used to calculate the primer pair efficiency. The PCR reactions were performed in 20 ml volumes with following parameters: 951C for 15min followed by 40 cycles of 941C for 20 s, 591C for 20 s, 721C for 20 s. The generation of specific PCR products was confirmed by melting curve analysis and gel electrophoresis. The data was analysed using the Lightcycler Software 4.0 with all samples normalized to b-actin.
Sodium dodecylsulfate-polyacrylamide gel electrophoresis and Western blotting Preparation of cell lysates and Western blotting was carried out as described (Reimertz et al., 2001) . The resulting blots were probed with a mouse monoclonal antiubiquitin antibody (Affiniti, Victoria, Canada) diluted 1:1000, a mouse monoclonal anti-PUMA/Bbc3 antibody (Han et al., 2001 ) diluted 1:1000, a rabbit polyclonal anti-Bim antibody (AAP-330; StressGen, Victoria, Canada) diluted 1:1000, or a mouse monoclonal anti-a-tubulin antibody (clone DM 1A; Sigma, Dublin, Ireland), diluted 1:5000. Horseradish peroxidase conjugated secondary antibodies (Pierce, Northumberland, UK) were detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce) and imaged using a FujiFilm LAS-3000 imaging system (Fuji, Sheffield, UK).
Determination of caspase-3-like protease activity DEVDase (Caspase-3-like) activity was determined fluorometrically using carbobenzoxy-Asp-Glu-Val-Asp-7-amino-4-methyl-coumarin (DEVD-AMC) as substrate. Cleavage of DEVD-AMC to liberate free AMC was monitored by measuring fluorescence after 1 and 2 h intervals. Protein content was determined using the Pierce Coomassie Plus Protein assay reagent (Perbio, Northumberland, UK). Caspase activity is expressed as change in fluorescent units per hour and per microgram protein.
Transient transfections and luciferase reporter gene assays Cells were transiently transfected in 24-well plates using Metafectene (Biontex) as per manufacturer's instruction. Transfection complexes consisted of 190 ng of a plasmid containing 0.9 kb of the PUMA promoter (a kind gift from Dr T Chittenden) along with 10 ng of a plasmid encoding for the Renilla luciferase (phRL-TK-luc; Promega, Southampton, UK) to normalize for transfection efficiency between experiments. At 16-24 h post-transfection cells were treated with Epoxo or vehicle for 24 h. Luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega) and resultant luminescence monitored using a Berthold Luminometer.
Hoechst staining of nuclear chromatin Cells cultured on 24-well plates were stained live with Hoechst 33258 (Sigma) at a final concentration of 1 mg/ml. After incubation for 10 min, nuclear morphology was observed using an Eclipse TE 300 inverted microscope (Nikon, Du¨sseldorf, Germany) and a 20 dry objective. For each time point and treatment, a total number of 300 cells were analysed for apoptotic morphology in three subfields of each culture. All experiments were performed at least twice with similar results.
Gene silencing with siRNA The annealed siRNA duplexes were purchased from Sigma Proligo (Paris, France). HCT116 cells were transfected with 100 nM of the appropriate duplex using Metafectene (Biontex, Martinsried/Planegg, Germany) as per manufacturer's instructions. Sequences used were: Bim sense 5 0 -CAAUUGU CUACCUUCUCGG(dTdT)-3 0 ; Bim antisense 5 0 -CCGAGAA GGUAGACAAUUG(dTdT)-3 0 ; control sense 5 0 -UUCUCCG AACGUGUCACGU(dTdT)-3 0 ; and control antisense 5 0 -AC GUGACACGUUCGGAGAA(dTdT)-3 0 . Twenty-four hours post-transfection cells were treated with 50 nM Epoxo or vehicle (DMSO) as control for 24 h.
Flow cytometry
Following treatments cells were stained with annexin V/ propidium iodide (BioVision, Mountain View, CA, USA) as per manufacturer's instructions. Samples were analysed immediately by flow cytometry. In all cases, a minimum of 10 4 events per sample were acquired. Flow cytometric analyses were performed on a CyFlow ML (Partec, Mu¨nster, Germany) followed by analysis using FloMax software.
Statistics
Data are given as means7s.e. For statistical comparison, t-test or one-way analysis of variance followed by Tukey test were employed using SPSS software (SPSS GmbH Software, Munich, Germany). P-values smaller than 0.05 were considered to be statistically significant.
Abbreviations
PUMA, p53 upregulated modulator of apoptosis; GRP78, immunoglobulin heavy chain-binding protein/78 kDa glucoseregulated protein; DMSO, dimethylsulfoxide; CHOP, C/EBPhomologous protein; Epoxo, epoxomicin; WT, wild type.
